1. Academic Validation
  2. Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy

Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy

  • Cancer Cell. 2015 Aug 10;28(2):225-39. doi: 10.1016/j.ccell.2015.07.002.
Roberto Ronca 1 Arianna Giacomini 2 Emanuela Di Salle 2 Daniela Coltrini 2 Katiuscia Pagano 3 Laura Ragona 3 Sara Matarazzo 2 Sara Rezzola 2 Daniele Maiolo 4 Rubben Torrella 5 Elisabetta Moroni 5 Roberta Mazzieri 6 Giulia Escobar 7 Marco Mor 8 Giorgio Colombo 5 Marco Presta 9
Affiliations

Affiliations

  • 1 Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy. Electronic address: roberto.ronca@unibs.it.
  • 2 Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
  • 3 NMR Laboratory, Istituto per lo Studio delle Macromolecole, CNR, 20133 Milan, Italy.
  • 4 Chemistry for Technologies Laboratory and INSTM, School of Engineering, University of Brescia, 25123 Brescia, Italy.
  • 5 Istituto di Chimica del Riconoscimento Molecolare, CNR, 20133 Milan, Italy.
  • 6 University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD 4102, Australia.
  • 7 San Raffaele Telethon Institute for Gene Therapy, 20132 Milan, Italy; Vita Salute San Raffaele University, 20132 Milan, Italy.
  • 8 Department of Pharmacy, University of Parma, 43121 Parma, Italy.
  • 9 Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy. Electronic address: marco.presta@unibs.it.
Abstract

The Fibroblast Growth Factor (FGF)/FGF receptor (FGFR) system plays a crucial role in Cancer by affecting tumor growth, angiogenesis, drug resistance, and escape from anti-angiogenic anti-vascular endothelial growth factor therapy. The soluble pattern recognition receptor long-pentraxin 3 (PTX3) acts as a multi-FGF antagonist. Here we demonstrate that human PTX3 overexpression in transgenic mice driven by the Tie2 promoter inhibits tumor growth, angiogenesis, and metastasis in heterotopic, orthotopic, and autochthonous FGF-dependent tumor models. Using pharmacophore modeling of the interaction of a minimal PTX3-derived FGF-binding pentapeptide with FGF2, we identified a small-molecule chemical (NSC12) that acts as an extracellular FGF trap with significant implications in Cancer therapy.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-107194
    99.07%, Anticancer Agent